Approximately 85% of GISTs harbor mutually exclusive activating mutations in KIT (exons 9, 11, 13, 17) or PDGFRA (exons 12, 18), driving constitutive receptor tyrosine kinase (RTK) activation and tumor progression (3, 10). The gene discussed is KIT; the disease is neoplasm.